Kezar Life Sciences, Inc.KZREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm focused on developing novel targeted therapies for patients with severe autoimmune diseases and unmet oncology medical needs. Its lead candidates modulate key immune pathways, with ongoing trials across core markets including North America and Europe.
KZR Q3 FY2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-21.9M
Net Profit
$-20.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.78
Kezar Life Sciences, Inc. Q3 FY2024 Financial Summary
Kezar Life Sciences, Inc. reported revenue of $0 for Q3 FY2024, with a net profit of $-20.3M (up 12.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-20.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2024 |
Income Statement
| Q3 2024 | |
|---|---|
| Revenue | $0 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2024 | |
|---|---|
| Assets | $164.1M |
| Liabilities | $30.0M |
| Equity | $134.0M |
Cash Flow
| Q3 2024 | |
|---|---|
| Operating CF | $-17.5M |